After a completed 24-week follow-up, patients in both intervention and control groups experienced a significant reduction in weight, BMI, ALT level, liver steatosis by CAP measurement, and fat mass by BIA compared to their respective levels at baseline (within group analysis). The gene discussed is GPT; the disease is Hepatic steatosis.